Acute Respiratory Infections

Resolution of symptoms in patients with acute respiratory infections (ARI) receiving antibiotic therapy and MUCINEX® D

See the poster

LaForce C, Skoner D.

Results from a multicenter, randomized, parallel-group, double-blind, placebo-controlled study showed that when used in combination with antibiotic therapy in patients with acute respiratory infections, MUCINEX® D was well tolerated, shortened time to relief, and improved respiratory symptoms better than placebo.

Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms

See the study

Albrecht H, Vernon M, Solomon G.

Respir Res. 2012;13:118.

Results from the study show that the scores from the 8 symptom-related questions in the Daily Cough and Phlegm Diary were robust and suitably reliable for use as efficacy endpoints in studies of expectorants, such as guaifenesin, for the symptoms of acute upper respiratory tract infections.

Guaifenesin and pseudoephedrine in an extended-release bi-layer tablet as first-line symptomatic therapy in patients with acute upper respiratory tract infections (URI): A randomized, double-blind, placebo-controlled, multicenter, parallel-group study

See the poster

Mariano Jr HG, Solomon G, Steward EC, Albrecht HH

Results show that the combination of 1200 mg guaifenesin and 120 mg pseudoephedrine HCl in an extended-release bi-layer tablet formulation offers a well-tolerated first-line symptomatic treatment that physicians can offer to patients instead of an antibiotic prescription for upper respiratory tract infections. A "wait and see" approach using a symptom-relieving product may reduce patients' desire for antibiotics and offer an alternative treatment without compromising patient satisfaction.